Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.49 |
| ▸ | AHCY | P23526 | 9/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.44 |
| ▸ | ADA | P00813 | 1/20 | 0.43 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.42 |
| ▸ | AHCYL1 | O43865 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15730603 | 0.78 | ALDH1A1 (0.54) | KDM4EALDH1A1GLAGAATSHR | |
| SCHEMBL4304214 | 0.78 | AHCY (0.49) | ADORA2AADORA1ADORA2BAHCYADA | |
| SCHEMBL4214819 | 0.77 | AHCY (0.56) | ADORA2AADORA1ADORA2BAHCYADA | |
| SCHEMBL30461799 | 0.76 | KDM4E (0.53) | KDM4EALDH1A1GLAGAATSHR | |
| SCHEMBL17873913 | 0.76 | ALDH1A1 (0.53) | KDM4EALDH1A1GLAGAATSHR | |
| SCHEMBL666503 | 0.76 | KDM4E (0.53) | KDM4EALDH1A1GLAGAATSHR | |
| SCHEMBL16747750 | 0.76 | ADA (0.56) | ADORA2AADORA1ADORA2BAHCYADA | |
| SCHEMBL21636974 | 0.76 | PI4KA (0.53) | ALDH1A1ADORA2AADORA1ADORA2BAHCY | |
| SCHEMBL18526508 | 0.76 | AHCY (0.59) | ADORA2AADORA1ADORA2BAHCYADA | |
| SCHEMBL24236874 | 0.74 | AHCY (0.43) | ADORA2AADORA1ADORA2BAHCYADA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239801-A1 | PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2024-07-18 | — | — | US | disclosed |
| US-20240239801-A1 | PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2024-07-18 | — | — | US | disclosed |
| US-20240218027-A1 | NUCLEOSIDE TRIPHOSPHATE TRANSPORTER AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2024-07-04 | — | — | US | disclosed |
| US-20240217971-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | Université de Montréal (CA) | 2024-07-04 | — | — | US | disclosed |
| WO-2024077391-A1 | THIAZOLO[5,4-D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | UNIVERSITE DE MONTREAL (CA) | 2024-04-18 | — | — | WO | disclosed |
| US-11834479-B2 | Nucleoside triphosphate transporter and uses thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-12-05 | — | — | US | disclosed |
| US-11761007-B2 | Production of unnatural nucleotides using a CRISPR/Cas9 system | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-09-19 | — | — | US | disclosed |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-20230149560-A1 | LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230149560-A1 | LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2011-01-27 | — | — | US | disclosed |
| US-20090291963-A1 | SUBSTITUTED INDOLES | SCHADT OLIVER | 2009-11-26 | — | — | US | disclosed |
| US-20090291963-A1 | SUBSTITUTED INDOLES | SCHADT OLIVER | 2009-11-26 | — | — | US | disclosed |
| WO-2009106419-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009098320-A2 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009099416-A1 | HETEROCYCLIC PEPTIDE KETOAMIDES | GEORGIA TECH RESEARCH CORPORATION (US) | 2009-08-13 | — | — | WO | disclosed |
| US-7572796-B2 | Substituted indoles | MERCK PATENT GMBH (DE) | 2009-08-11 | — | — | US | disclosed |
| US-7572796-B2 | Substituted indoles | MERCK PATENT GMBH (DE) | 2009-08-11 | — | — | US | disclosed |
| US-20090054459-A1 | Substituted indoles | SCHADT OLIVER | 2009-02-26 | — | — | US | disclosed |
| US-20090054459-A1 | Substituted indoles | SCHADT OLIVER | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149560-A1 | LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF | STING1, CGAS, TLR9 | KDM4E 3466/4885ALDH1A1 4863/4885GLA 3595/4885 |
| US-20090054459-A1 | Substituted indoles | TPH2, TPH1, HTR1A | KDM4E 2189/4885ALDH1A1 1722/4885GLA 1825/4885 |
| US-20090291963-A1 | SUBSTITUTED INDOLES | TPH2, TPH1, HTR1A | KDM4E 2277/4885ALDH1A1 1420/4885GLA 1592/4885 |
| US-20240218027-A1 | NUCLEOSIDE TRIPHOSPHATE TRANSPORTER AND USES THEREOF | SLC35B2, SLC29A2, PNP | KDM4E 4151/4885ALDH1A1 2777/4885GLA 2739/4885 |
| US-20240239801-A1 | PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | NRAS, BRAF, KRAS | KDM4E 2695/4885ALDH1A1 1786/4885GLA 3156/4885 |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | MRPS22, MRPS23, MRPL12 | KDM4E 4433/4885ALDH1A1 3239/4885GLA 943/4885 |
| US-20240217971-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | BRAF, NRAS, DPYD | KDM4E 2840/4885ALDH1A1 1619/4885GLA 2094/4885 |
| US-11834479-B2 | Nucleoside triphosphate transporter and uses thereof | SLC35B2, SLC29A2, PNP | KDM4E 4151/4885ALDH1A1 2777/4885GLA 2739/4885 |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | KDM4E 4005/4885ALDH1A1 4105/4885GLA 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.